SIETES :: 92881 citas

Resultados de la búsqueda por HIPNOSEDANTES REFINAR BÚSQUEDA

1.

Anónimo. Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug safety communication - Serious breathing problems. U.S. Food and Drug Administration 2019:19 de diciembre. [Ref.ID 103239]

2.

Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Texeira J. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. Psychopharmacology (Berl) 2019:noviermbre. [Ref.ID 103227]

3.

Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Strang J, Hickman M. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLOS Medicine 2019:26 de noviembre. [Ref.ID 103216]

4.

Piovani D, Clavenna A, Bonati M. Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data. Eur J Clin Pharmacol 2019;75:octubre. [Ref.ID 103184]

5.

Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]

6.

Anónimo. FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines. Updated warnings for eszopiclone, zaleplon and zolpidem. U.S. Food and Drug Administration 2019:30 de abril. [Ref.ID 103113]

7.

Slee A, Nazareth I, Bondaronek P, Liu Y, Chenq Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019;393:23 de febrero. [Ref.ID 103110]

8.

Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]

9.

Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case–control study. Drug Saf 2019;42:enero. [Ref.ID 103028]

10.

Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]

11.

Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. National Vital Statistics Reports 2018;67:12 de diciembre. [Ref.ID 102871]

12.

Anónimo. “Benzos” mixed with opioids are playing an increased role in overdose deaths.. DIA Daily 2018:8. [Ref.ID 102870]

13.

Cadogan CA, Ryan C, Cahir C, Bradley CP, Bennett K. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102807]

14.

Lalic S, Gisev N, Bell JS, Korhonen MJ, Ilomäki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102804]

15.

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

16.

Anónimo. Study shows that nearly half of overdose deaths are from fentanyl. DIA Daily 2018:3. [Ref.ID 102704]

17.

Klein LR, Driver BE, Miner JR, Martel ML, Hessel M, Collins JD, Horton GB, Fagerstrom E, Satpathy R, Cole JB. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. Ann Emerg Med 2018:6 de junio. [Ref.ID 102665]

18.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

19.

Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102557]

20.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]